Description

CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–COVID-19-immunoregulation–C151H243N39O37—-[1]Yaqi Tan, et al. Chemokine-like factor 1-derived C-terminal peptides induce the proliferation of dermal microvascular endothelial cells in psoriasis. PLoS One. 2015 Apr 27;10(4):e0125073.–891861-48-6–3196.78–98.50–O=C([C@H]1N(CCC1)C(CNC([C@H](CO)NC([C@H]2N(CCC2)C([C@H](CC(N)=O)NC([C@@H](NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H]([C@@H](C)CC)NC([C@H](CC(C)C)NC([C@@H](N)C)=O)=O)=O)CC3=CC=C(C=C3)O)=O)=O)=O)=O)=O)CC4=CC=CC=C4)=O)=O)=O)=O)=O)N[C@@H](CC5=CC=C(C=C5)O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N6[C@@H](CCC6)C(N[C@@H](C(C)C)C(N[C@H](C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](C(C)C)C(N[C@H](C(O)=O)CC(C)C)=O)=O)=O)=O)=O)=O)CC7=CN=CN7)=O)=O)=O)=O)=O)=O–Inflammation/Immunology–10 mM in DMSO–CCR;ERK–CCR4;ERK1;ERK2–GPCR/G Protein;Immunology/Inflammation;MAPK/ERK Pathway;Stem Cell/Wnt–Peptides